Intraductal Pancreatic Cancer is Less Responsive Than Cancer in the Stroma to Neoadjuvant Chemotherapy

June 05, 2020 | Histopathology

Lab.Equipment is always here to make sure you're updated on the latest Pathology industry news. Check out what we have freshly curated from Laboratory Investigation today for you:

Neoadjuvant chemotherapy (NAC) is often the treatment of choice for borderline resectable and locally advanced invasive pancreatic ductal adenocarcinoma (PDAC); however, most cancers only partially respond to therapy. We hypothesized that the location of residual neoplastic cells in resected specimens following NAC could provide a clue as to the mechanisms of resistance. PDAC cells invade the stroma but can also invade back into and spread via the pancreatic ducts, which has been referred to as “cancerization of ducts” (COD). We compared the responsiveness to chemotherapy between PDAC cells in the stroma and PDAC cells in the duct. Pancreatic resections from a total of 174.. More of this in the Laboratory Investigation Blog.

If you're in the Histopath industry and are looking for multipurpose Histopath lab equipment for clinical medicine or tissue preparation or basic and advanced applications, then you have come to the right place. Lab.Equipment provides a range of equipment for facilities analyzing and running histopath tests. Check out our highly-recommended Histopath equipment including:

Discover user-friendly and robust products to meet your specific application demands by shopping our product portfolio from well-established manufacturers like:

Running other applications? You can rely on Lab.Equipment for much needed help. Boost laboratory efficiency and productivity with lab equipment for other industries including pharmaceutical, environmental, forensics, and more. Check out what you require for your application here.

Back To Top
We are fully compliant with the GDPR laws. We promise to safeguard your data and protect your privacy rights.